188 related articles for article (PubMed ID: 37075701)
1. A kinome-wide CRISPR screen identifies CK1α as a target to overcome enzalutamide resistance of prostate cancer.
Liu J; Zhao Y; He D; Jones KM; Tang S; Allison DB; Zhang Y; Chen J; Zhang Q; Wang X; Li C; Wang C; Li L; Liu X
Cell Rep Med; 2023 Apr; 4(4):101015. PubMed ID: 37075701
[TBL] [Abstract][Full Text] [Related]
2. Circulating-tumor DNA as predictor of enzalutamide response post-abiraterone treatment in metastatic castration-resistant prostate cancer.
Moses M; Niu A; Lilly MB; Hahn AW; Nussenzveig R; Ledet E; Manogue C; Cotogno P; Lewis B; Layton J; Agarwal N; Sartor O; Barata PC
Cancer Treat Res Commun; 2020; 24():100193. PubMed ID: 32702615
[TBL] [Abstract][Full Text] [Related]
3. Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors.
Zhu Y; Dalrymple SL; Coleman I; Zheng SL; Xu J; Hooper JE; Antonarakis ES; De Marzo AM; Meeker AK; Nelson PS; Isaacs WB; Denmeade SR; Luo J; Brennen WN; Isaacs JT
Oncogene; 2020 Nov; 39(45):6935-6949. PubMed ID: 32989253
[TBL] [Abstract][Full Text] [Related]
4. Enhanced radiosensitization of enzalutamide via schedule dependent administration to androgen-sensitive prostate cancer cells.
Ghashghaei M; Niazi TM; Heravi M; Bekerat H; Trifiro M; Paliouras M; Muanza T
Prostate; 2018 Jan; 78(1):64-75. PubMed ID: 29134684
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Response to Enzalutamide Consecutively After Abiraterone Acetate/Prednisone Failure in Patients With Metastatic Castration-resistant Prostate Cancer.
Emamekhoo H; Barata PC; Edwin NC; Woo KM; Grivas P; Garcia JA
Clin Genitourin Cancer; 2018 Dec; 16(6):429-436. PubMed ID: 30236961
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic/Pharmacodynamic Relationship of Enzalutamide and Its Active Metabolite N-Desmethyl Enzalutamide in Metastatic Castration-Resistant Prostate Cancer Patients.
Joulia ML; Carton E; Jouinot A; Allard M; Huillard O; Khoudour N; Peyromaure M; Zerbib M; Schoemann AT; Vidal M; Goldwasser F; Alexandre J; Blanchet B
Clin Genitourin Cancer; 2020 Apr; 18(2):155-160. PubMed ID: 31630979
[TBL] [Abstract][Full Text] [Related]
7. Abiraterone Followed by Enzalutamide Versus Enzalutamide Followed by Abiraterone in Chemotherapy-naive Patients With Metastatic Castration-resistant Prostate Cancer.
Matsubara N; Yamada Y; Tabata KI; Satoh T; Kamiya N; Suzuki H; Kawahara T; Uemura H; Yano A; Kawakami S; Otsuka M; Fukasawa S
Clin Genitourin Cancer; 2018 Apr; 16(2):142-148. PubMed ID: 29042308
[TBL] [Abstract][Full Text] [Related]
8. [
Emmett L; Subramaniam S; Crumbaker M; Nguyen A; Joshua AM; Weickhardt A; Lee ST; Ng S; Francis RJ; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Gedye C; Rutherford NK; Sandhu S; Kumar AR; Pook D; Ramdave S; Nadebaum DP; Voskoboynik M; Redfern AD; Macdonald W; Krieger L; Schembri G; Chua W; Lin P; Horvath L; Bastick P; Butler P; Zhang AY; Yip S; Thomas H; Langford A; Hofman MS; McJannett M; Martin AJ; Stockler MR; Davis ID;
Lancet Oncol; 2024 May; 25(5):563-571. PubMed ID: 38621400
[TBL] [Abstract][Full Text] [Related]
9. Targeting autophagy overcomes Enzalutamide resistance in castration-resistant prostate cancer cells and improves therapeutic response in a xenograft model.
Nguyen HG; Yang JC; Kung HJ; Shi XB; Tilki D; Lara PN; DeVere White RW; Gao AC; Evans CP
Oncogene; 2014 Sep; 33(36):4521-30. PubMed ID: 24662833
[TBL] [Abstract][Full Text] [Related]
10. Influence of abiraterone and enzalutamide on body composition in patients with metastatic castration resistant prostate cancer.
Fischer S; Clements S; McWilliam A; Green A; Descamps T; Oing C; Gillessen S
Cancer Treat Res Commun; 2020; 25():100256. PubMed ID: 33307509
[TBL] [Abstract][Full Text] [Related]
11. Proteome profiling of enzalutamide-resistant cell lines and serum analysis identified ALCAM as marker of resistance in castration-resistant prostate cancer.
Csizmarik A; Keresztes D; Nagy N; Bracht T; Sitek B; Witzke K; Puhr M; Tornyi I; Lázár J; Takács L; Kramer G; Sevcenco S; Maj-Hes A; Jurányi Z; Hadaschik B; Nyirády P; Szarvas T
Int J Cancer; 2022 Oct; 151(8):1405-1419. PubMed ID: 35689436
[TBL] [Abstract][Full Text] [Related]
12. N-Myc promotes therapeutic resistance development of neuroendocrine prostate cancer by differentially regulating miR-421/ATM pathway.
Yin Y; Xu L; Chang Y; Zeng T; Chen X; Wang A; Groth J; Foo WC; Liang C; Hu H; Huang J
Mol Cancer; 2019 Jan; 18(1):11. PubMed ID: 30657058
[TBL] [Abstract][Full Text] [Related]
13. Prostate cancer cells survive anti-androgen and mitochondrial metabolic inhibitors by modulating glycolysis and mitochondrial metabolic activities.
Basu HS; Wilganowski N; Robertson S; Reuben JM; Cohen EN; Zurita A; Ramachandran S; Xiao LC; Titus M; Wilding G
Prostate; 2021 Sep; 81(12):799-811. PubMed ID: 34170017
[TBL] [Abstract][Full Text] [Related]
14. [Establishment of enzalutamide-resistant human prostate cancer cell lines and screening of lncRNA and mRNA expression profiles].
Guan H; Ling ZX; Fang F; Mao LK; You ZH; Wang C; Chen SQ; Xu B; Chen M
Zhonghua Nan Ke Xue; 2018 Feb; 24(2):116-121. PubMed ID: 30156069
[TBL] [Abstract][Full Text] [Related]
15. Treatment of Metastatic Castration-resistant Prostate Cancer With Abiraterone and Enzalutamide Despite PSA Progression.
Becker DJ; Iyengar AD; Punekar SR; Ng J; Zaman A; Loeb S; Becker KD; Makarov D
Anticancer Res; 2019 May; 39(5):2467-2473. PubMed ID: 31092441
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of noncanonical Wnt pathway overcomes enzalutamide resistance in castration-resistant prostate cancer.
Chen X; Liu J; Cheng L; Li C; Zhang Z; Bai Y; Wang R; Han T; Huang C; Kong Y; Feng F; Liu X
Prostate; 2020 Feb; 80(3):256-266. PubMed ID: 31856338
[TBL] [Abstract][Full Text] [Related]
17. Developing a Novel Enzalutamide-Resistant Prostate Cancer Model via AR F877L Mutation in LNCaP Cells.
Wang R; Ma S; Xu N; Gan Y; Li P; Zhang J; Zhang Z; Gu Q; Xiang J
Curr Protoc; 2024 Apr; 4(4):e1033. PubMed ID: 38652202
[TBL] [Abstract][Full Text] [Related]
18. ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).
Emmett L; Subramaniam S; Joshua AM; Crumbaker M; Martin A; Zhang AY; Rana N; Langford A; Mitchell J; Yip S; Francis R; Hofman MS; Sandhu S; Azad A; Gedye C; McJannett M; Stockler MR; Davis ID;
BJU Int; 2021 Nov; 128(5):642-651. PubMed ID: 34028967
[TBL] [Abstract][Full Text] [Related]
19. Identification of a Radiosensitivity Molecular Signature Induced by Enzalutamide in Hormone-sensitive and Hormone-resistant Prostate Cancer Cells.
Ghashghaei M; Niazi TM; Aguilar-Mahecha A; Klein KO; Greenwood CMT; Basik M; Muanza TM
Sci Rep; 2019 Jun; 9(1):8838. PubMed ID: 31221986
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of CXCR7 is a Novel Indicator for Enzalutamide Resistance in Castration-Resistant Prostate Cancer Patients.
Luo Y; Li Q; Yang X; Wei D; Feng B; Li M; Han Y; Zhao J; Lin Y; Li Q; Hou Z; Zhuang H; Jiang Y
Dis Markers; 2021; 2021():6649579. PubMed ID: 34413914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
